Sutro Biopharma Statistics

Total Valuation

Sutro Biopharma has a market cap or net worth of $65.45 million. The enterprise value is -$118.56 million.

Market Cap	65.45M
Enterprise Value	-118.56M

Important Dates

The last earnings date was Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Sutro Biopharma has 84.77 million shares outstanding. The number of shares has increased by 25.76% in one year.

Current Share Class	84.77M
Shares Outstanding	84.77M
Shares Change (YoY)	+25.76%
Shares Change (QoQ)	+1.77%
Owned by Insiders (%)	1.55%
Owned by Institutions (%)	43.40%
Float	61.40M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.62
Forward PS	1.46
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.12

Current Ratio	3.12
Quick Ratio	2.87
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-4.70

Financial Efficiency

Return on equity (ROE) is -347.64% and return on invested capital (ROIC) is -124.54%.

Return on Equity (ROE)	-347.64%
Return on Assets (ROA)	-27.54%
Return on Invested Capital (ROIC)	-124.54%
Return on Capital Employed (ROCE)	-88.02%
Revenue Per Employee	$337,010
Profits Per Employee	-$673,216
Employee Count	310
Asset Turnover	0.28
Inventory Turnover	n/a

Taxes

In the past 12 months, Sutro Biopharma has paid $2.34 million in taxes.

Income Tax	2.34M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -76.17% in the last 52 weeks. The beta is 1.67, so Sutro Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.67
52-Week Price Change	-76.17%
50-Day Moving Average	0.81
200-Day Moving Average	1.52
Relative Strength Index (RSI)	43.79
Average Volume (20 Days)	456,019

Short Selling Information

The latest short interest is 3.38 million, so 3.99% of the outstanding shares have been sold short.

Short Interest	3.38M
Short Previous Month	3.66M
Short % of Shares Out	3.99%
Short % of Float	5.51%
Short Ratio (days to cover)	6.15

Income Statement

In the last 12 months, Sutro Biopharma had revenue of $104.47 million and -$208.70 million in losses. Loss per share was -$2.51.

Revenue	104.47M
Gross Profit	120.95M
Operating Income	-165.57M
Pretax Income	-97.16M
Net Income	-208.70M
EBITDA	-158.10M
EBIT	-165.57M
Loss Per Share	-$2.51

Full Income Statement

Balance Sheet

The company has $205.13 million in cash and $19.59 million in debt, giving a net cash position of $185.54 million or $2.19 per share.

Cash & Cash Equivalents	205.13M
Total Debt	19.59M
Net Cash	185.54M
Net Cash Per Share	$2.19
Equity (Book Value)	-32.11M
Book Value Per Share	-0.38
Working Capital	157.38M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$248.86 million and capital expenditures -$3.16 million, giving a free cash flow of -$252.02 million.

Operating Cash Flow	-248.86M
Capital Expenditures	-3.16M
Free Cash Flow	-252.02M
FCF Per Share	-$2.97

Full Cash Flow Statement

Margins

Gross margin is 115.77%, with operating and profit margins of -158.48% and -199.76%.

Gross Margin	115.77%
Operating Margin	-158.48%
Pretax Margin	-197.52%
Profit Margin	-199.76%
EBITDA Margin	-151.33%
EBIT Margin	-158.48%
FCF Margin	n/a

Dividends & Yields

Sutro Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-25.76%
Shareholder Yield	-25.76%
Earnings Yield	-311.58%
FCF Yield	-376.26%

Analyst Forecast

The average price target for Sutro Biopharma is $3.83, which is 396.11% higher than the current price. The consensus rating is "Hold".

Price Target	$3.83
Price Target Difference	396.11%
Analyst Consensus	Hold
Analyst Count	8
Revenue Growth Forecast (5Y)	-2.43%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sutro Biopharma has an Altman Z-Score of -5.23 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.23
Piotroski F-Score	1